Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial.
Saved in:
| Title: | Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. |
|---|---|
| Authors: | Schlaich MP; Dobney Hypertension Centre, Royal Perth Hospital Research Foundation, Medical School, The University of Western Australia, Perth, WA, Australia; Department of Cardiology and Department of Nephrology, Royal Perth Hospital, Perth, WA, Australia. Electronic address: markus.schlaich@uwa.edu.au., Bellet M; Global Clinical Development, Idorsia Pharmaceuticals, Allschwil, Switzerland., Weber MA; Downstate College of Medicine, State University of New York, Brooklyn, NY, USA., Danaietash P; Global Clinical Development, Idorsia Pharmaceuticals, Allschwil, Switzerland., Bakris GL; Department of Medicine, American Heart Association Comprehensive Hypertension Center, The University of Chicago Medicine, Chicago, IL, USA., Flack JM; Division of General Internal Medicine, Hypertension Section, Department of Medicine, Hypertension Section, Southern Illinois University School of Medicine, Springfield, IL, USA., Dreier RF; Global Clinical Development, Idorsia Pharmaceuticals, Allschwil, Switzerland., Sassi-Sayadi M; Department of Biometry, Idorsia Pharmaceuticals, Allschwil, Switzerland., Haskell LP; The Janssen Pharmaceutical Companies of Johnson & Johnson, Raritan, NJ, USA., Narkiewicz K; Department of Hypertension and Diabetology, Medical University of Gdańsk, Gdańsk, Poland., Wang JG; Department of Hypertension, The Shanghai Institute of Hypertension, Rui Jin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China. |
| Corporate Authors: | PRECISION investigators |
| Source: | Lancet (London, England) [Lancet] 2022 Dec 03; Vol. 400 (10367), pp. 1927-1937. Date of Electronic Publication: 2022 Nov 07. |
| Publication Type: | Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III; Journal Article |
| Journal Info: | Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
